Aaron Sanyal

Dr. Aaron Sanyal is a prominent researcher at the University of Virginia Commonwealth, recognized for his work in the field of metabolic diseases, particularly focusing on the treatment of metabolic dysfunction-associated steatotic liver disease (MASH). He recently co-led a significant clinical trial assessing the efficacy of semaglutide, a drug that has shown promising results in reducing liver fat and inflammation in patients with MASH.